KEY CAPITAL CORPORATION announced the company has entered into an agreement with Hospital Reina de Los Herreros in Antigua, Guatemala to establish an Immunotherapy Research and Treatment Center to especially treat patients with late-stage or terminal cancers. It is expected that the Center will formally open at the hospital within the next 90 days. Guatemala and Central America have a high incidence of cancer, with a large portion of their population having little to no treatment options, especially in late-stage and terminal liver and pancreatic cancer cases. Providing a treatment program to research and meet this unmet medical need will be a priority for the Immunotherapy Research and Treatment Center as it trials the Immunitor Inc., immunotherapeutic vaccine in order to receive formal marketing approval in Latin America. In preparation of the establishment of the Immunotherapy Research and Treatment Center a dedicated hospital wing has been renovated over the past six months and advanced diagnostic, screening, and monitoring facilities have been installed.